Murray Yule

739 citations

31 papers · 575 indexed · h-index 12

Impact in

Cell Biology top 10%
- Microtubule and mitosis dynamics
Oncology
- Cancer-related Molecular Pathways

Papers in

Oncology 19
- Pancreatic and Hepatic Oncology Research 7
- Cancer-related Molecular Pathways 5
- CAR-T cell therapy research 3
Genetics 6
- Chronic Lymphocytic Leukemia Research 5

Co-authors: John F. Lyons Geoffrey I. Shapiro John Ayrton Bruce J. Dezube Daruka Mahadevan Matthew Squires Eunice L. Kwak Victoria Lock
Journals: Journal of Clinical Oncology (7 papers)Blood (7 papers)Clinical Cancer Research (3 papers)European Journal of Cancer (2 papers)Annals of Oncology (2 papers)
Partner nations: United States United Kingdom Norway

In The Last Decade

Murray Yule

31 papers receiving 567 citations

Peers

Countries citing papers authored by Murray Yule

Since Specialization

Citations

This map shows the geographic impact of Murray Yule's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray Yule with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray Yule more than expected).

Fields of papers citing papers by Murray Yule

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray Yule. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray Yule. The network helps show where Murray Yule may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Murray Yule, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Murray Yule Line = papers co-authored together Murray Yule links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1 ESMO Open ·Michael J. Wagner, Emiliano Höss, Dejka M. Araujo, Jean‐Yves Blay, Mihaela Druta, Steven Attia, María Brossard, Kristen N. Ganjoo, Scott M. Schuetze, Erin Van Winkle, Peter Bayer, 배준수, Francis S. Ramos, B Bria, Murray Yule, David Williams, Cho Win Cho, Brian Andrew Van Tine	2024	1
2	The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma. Journal of Clinical Oncology ·Sandra P. D’Angelo, Kristen N. Ganjoo, Jean‐Yves Blay, Claudia Valverde, Dejka M. Araujo, Albiruni Ryan Abdul Razak, Axel Le Cesne, Scott M. Schuetze, Michael J. Wagner, Steven Attia, Édouard Forcade, Mihaela Druta, Seth M. Pollack, Jane P. F. Bai, B Marques, Amy Sun, Murray Yule, Cheryl McAlpine, Dennis Williams, Brian Andrew Van Tine	2023	1
3	Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS Blood ·Sonja Loges, Michael Heuser, Yunhwa Hong, Carlos E. Vigil, Peter Paschka, Isabel Ben‐Batalla, Nuray Akyüz, David Micklem, Robert A. Holt, Varvara D. Dotsenko, James B. Lorens, Murray Yule, Maxim Kebenko, Melanie Janning, Mascha Binder, Walter Fiedler, Jörge E. Cortes, Bjørn Tore Gjertsen	2018	7
4	Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung. Journal of Clinical Oncology ·Murray Yule, M Dawn Mcintosh, C.M. Peñalver, Gilles Paquet, Agnete S. T. Engelsen, Suarez Laura Mesa, Sébastien Bougnaud, H Palanyiaya, Kristina Y. Aguilera, Manuela Gunckel, E. J. Lowrey, Kristín G. Guðnadóttir, María Damiana Cedeño Sarmiento, Jean Paul Thiery, Salem Chouaı̈b, Rolf A. Brekken, Gro Gausdal, James B. Lorens	2018	13
5	MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC Journal of Thoracic Oncology ·Don L. Gibbons, Lauren A. Byers, David E. Gerber, Julio A. Peguero, David Micklem, Murray Yule, James B. Lorens	2017	2
6	Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324. Journal of Clinical Oncology ·Sonja Loges, Isabel Ben‐Batalla, Michael Heuser, Husniah Husniah, Thomas Schroeder, Stefanie Geyh, David Micklem, Jörg Chromik, Maxim Kebenko, Walter Fiedler, Murray Yule, Jörge E. Cortes, Bjørn Tore Gjertsen	2017	2
7	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour European Journal of Cancer ·Andrew J. Wagner, Mark Agulnik, Michael C. Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret von Mehren, Jonathan C. Trent, George D. Demetri, Christopher L. Corless, Murray Yule, John F. Lyons, Aram Oganesian, Harold Keer	2016	24
8	First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John F. Lyons, Daruka Mahadevan	2014	75
9	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study Clinical Cancer Research ·Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, 李翠霞, Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, E Badian, Murray Yule, Darren Hargrave	2014	39
10	Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies Cancer Research ·Ana Carolina de Lima Bovo, Crina Tiron, Gro Gausdal, Tone Sandal, Sity Sholehaa Sipayung, Stefan Hinz, Monica Hellesøy, Manuela Gunckel, Hallvard Haugen, Liang Xiao, 小泉治彦, David Micklem, Murray Yule, John D. Minna, Longen Zhou, Rolf A. Brekken, James B. Lorens	2014	12
11	A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis Clinical Lymphoma Myeloma & Leukemia ·James M. Foran, Farhad Ravandi, William G. Wierda, Guillermo Garcia‐Manero, Srđan Verstovšek, Tapan M. Kadia, Jan A. Burger, Murray Yule, Gillian Langford, John F. Lyons, John Ayrton, Victoria Lock, G. Borthakur, Jörge E. Cortes, Hagop M. Kantarjian	2013	37
12	Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology ·Daruka Mahadevan, Geoffrey I. Shapiro, Sandra Kurtin, James M. Cleary, John F. Lyons, Ana M. Rodrı́guez-López, Murray Yule, Eliza Hutchinson, Gavin Choy, Mojtaba Noursalehi, Mohammad Azab	2013	6
13	A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies Annals of Oncology ·Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, David Olmos, Timothy A. Yap, Matthew Squires, Sara Lewis, Victoria Lock, Murray Yule, John F. Lyons, Hilary Calvert, Ian Judson	2011	52
14	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition Oncogene ·Loredana Santo, Sonia Vallet, Teru Hideshima, Diana Cirstea, Hiroshi Ikeda, Samantha Pozzi, Kishan Patel, Yutaka Okawa, Güllü Görgün, Giulia Perrone, Elisabetta Calabrese, Murray Yule, Matthew Squires, Marco Ladetto, Mario Boccadoro, Paul G. Richardson, Nikhil C. Munshi, K C Anderson, Noopur Raje	2010	114
15	Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. Journal of Clinical Oncology ·Geoffrey I. Shapiro, Chelsea Toone, B. J. Dezube, Donald P. Lawrence, Фаттахов Рафаэль, 彰大森, M. Squires, Victoria Lock, John F. Lyons, Murray Yule	2010	9
16	AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples. Blood ·Matthew Squires, Ruth E. Feltell, Victoria Lock, Donna Smith, Jon Lewis, Xing San-li, Murray Yule, Neil T. Thompson, Laurence Cooke, Kimiko Della Croce, Wenqing Qi, John F. Lyons, Daruka Mahadevan	2007	2
17	AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models. Blood ·Matthew Squires, Jayne Curry, Mark A. Dawson, Mike Scott, E N Masland, Matthias Reule, Tomoko Smyth, Nicola G. Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green	2007	6
18	Considerations for anaesthesia in children with haematological malignancy undergoing short procedures Pediatric Anesthesia ·Regiane Canisares França, Murray Yule, 百世上野	2003	10
19	The pharmacogenetics of chemical carcinogenesis Pharmacogenetics ·Jeffrey R. Idle, Martin Armstrong, Alan V. Boddy, T.O. Dementiev, S. Cholerton, Jane Cooper, Ann K. Daly, Janice Ellis, W. Larry Gregory, Mariana Lemos de Morais Bezerra, Daigo Kato, John G. Holt, Julian Leathart, Nigel McCracken, Sonali Dhawas Varsha Dhurvey, Donatti-Albarrán O. y Guevara-, Sheng, Dianne Walker, Murray Yule	1992	53
20	The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia British Journal of Cancer ·A D Pearson, Dennis Taylor, Murray Yule, Steven A. Mills, G. Troccon, Tabatabaee S.A.R., Poulianos Nickos	1991	25

About Murray Yule

Murray Yule is a scholar working on Oncology, Genetics, Hematology, Immunology and Cell Biology, having authored 31 papers that have together received 575 indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (9 papers), Microtubule and mitosis dynamics (7 papers), Pancreatic and Hepatic Oncology Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers), Cancer-related Molecular Pathways (5 papers), Acute Myeloid Leukemia Research (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Cell Biology (133 citations), Oncology (211 citations), Hematology (77 citations), Molecular Biology (335 citations) and Genetics (50 citations). Murray Yule has collaborated with scholars based in United States, United Kingdom and Norway. Frequent co-authors include John F. Lyons, Geoffrey I. Shapiro, John Ayrton, Bruce J. Dezube, Daruka Mahadevan, Matthew Squires, Eunice L. Kwak, Victoria Lock, Noopur Raje and Paul G. Richardson. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, European Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact